ALSO NOTED: Sinclair Pharma shares drop; Korea cracks down on bribery;

> Sinclair Pharma saw its shares drop 12 percent after its marketing partner OraPharma delayed the U.S. introduction of Decapinol, a mouth rinse for gum disease. Report

> A new study shows the abortion pill is no more dangerous than the surgical form of abortion. Some researchers had theorized that use of RU-486 might increase the risk of future miscarriage or tubal pregnancy; those fears appear to be unfounded. Report

> Korean regulators have caught 17 mid-size and large drug makers bribing hospitals with rebates, the country's Fair Trade Commission announced. Its anti-bribery crackdown will now expand to 200 small local drug companies, the agency said. The names of the companies involved were not released. Report

And Finally... When Warren Buffett invests in your company, the attention is a backhanded compliment: Buffett tends to nab you when you're down, so if he's buying, you're not flying. And right now, his eyes appear to be on Pharma. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.